Abstract
Background Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) frequently causes feeding artery stenosis or occlusion that may interfere with repeated treatment. Purpose To investigate the incidence and predictors of hepatic arterial damage (HAD) after drug-eluting bead-TACE (DEB-TACE) in comparison with conventional TACE (Conv-TACE). Material and Methods We retrospectively analyzed 54 patients who underwent DEB-TACE for HCC as an initial treatment with follow-up angiography and 54 patients who underwent Conv-TACE using doxorubicin-lipiodol mixture and gelfoam particles for comparison. HAD was evaluated after a single session of TACE and graded as follows: grade I, no significant wall irregularity; grade II, overt stenosis; grade III, occlusion. Results The incidence of HAD was significantly higher in the DEB-TACE group than the Conv-TACE group when analyzed per branch (odds ratio [OR], 6.36; P < 0.001) and per patient (OR, 3.15; P = 0.005). For each HAD grade, the mean doxorubicin dose was greater in the DEB-TACE group than in the Conv-TACE group (P < 0.001, P = 0.053, and P = 0.01 for grades I, II, and III, respectively). In multivariate analysis, risk factors of HAD included mean doxorubicin dose and selective embolization in the Conv-TACE group (P = 0.03 and P < 0.001, respectively) and mean doxorubicin dose in the DEB-TACE group (P = 0.004). Conclusion The incidence and grade of HAD were higher after DEB-TACE compared to Conv-TACE with doxorubicin dose as a possible risk factor. HAD was independent of overall survival in both groups.
| Original language | English |
|---|---|
| Pages (from-to) | 131-139 |
| Number of pages | 9 |
| Journal | Acta Radiologica |
| Volume | 58 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2017 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Radiological and Ultrasound Technology
- Radiology Nuclear Medicine and imaging
Cite this
}
Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma : Comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study. / Lee, Seungsoo; Kim, Kyoung Min; Lee, Shin Jae; Lee, Kwang Hun; Lee, Do Yun; Kim, ManDeuk; kim, doyoung; Kim, Seungup; Won, Jong Yun.
In: Acta Radiologica, Vol. 58, No. 2, 01.01.2017, p. 131-139.Research output: Contribution to journal › Article
TY - JOUR
T1 - Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma
T2 - Comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study
AU - Lee, Seungsoo
AU - Kim, Kyoung Min
AU - Lee, Shin Jae
AU - Lee, Kwang Hun
AU - Lee, Do Yun
AU - Kim, ManDeuk
AU - kim, doyoung
AU - Kim, Seungup
AU - Won, Jong Yun
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Background Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) frequently causes feeding artery stenosis or occlusion that may interfere with repeated treatment. Purpose To investigate the incidence and predictors of hepatic arterial damage (HAD) after drug-eluting bead-TACE (DEB-TACE) in comparison with conventional TACE (Conv-TACE). Material and Methods We retrospectively analyzed 54 patients who underwent DEB-TACE for HCC as an initial treatment with follow-up angiography and 54 patients who underwent Conv-TACE using doxorubicin-lipiodol mixture and gelfoam particles for comparison. HAD was evaluated after a single session of TACE and graded as follows: grade I, no significant wall irregularity; grade II, overt stenosis; grade III, occlusion. Results The incidence of HAD was significantly higher in the DEB-TACE group than the Conv-TACE group when analyzed per branch (odds ratio [OR], 6.36; P < 0.001) and per patient (OR, 3.15; P = 0.005). For each HAD grade, the mean doxorubicin dose was greater in the DEB-TACE group than in the Conv-TACE group (P < 0.001, P = 0.053, and P = 0.01 for grades I, II, and III, respectively). In multivariate analysis, risk factors of HAD included mean doxorubicin dose and selective embolization in the Conv-TACE group (P = 0.03 and P < 0.001, respectively) and mean doxorubicin dose in the DEB-TACE group (P = 0.004). Conclusion The incidence and grade of HAD were higher after DEB-TACE compared to Conv-TACE with doxorubicin dose as a possible risk factor. HAD was independent of overall survival in both groups.
AB - Background Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) frequently causes feeding artery stenosis or occlusion that may interfere with repeated treatment. Purpose To investigate the incidence and predictors of hepatic arterial damage (HAD) after drug-eluting bead-TACE (DEB-TACE) in comparison with conventional TACE (Conv-TACE). Material and Methods We retrospectively analyzed 54 patients who underwent DEB-TACE for HCC as an initial treatment with follow-up angiography and 54 patients who underwent Conv-TACE using doxorubicin-lipiodol mixture and gelfoam particles for comparison. HAD was evaluated after a single session of TACE and graded as follows: grade I, no significant wall irregularity; grade II, overt stenosis; grade III, occlusion. Results The incidence of HAD was significantly higher in the DEB-TACE group than the Conv-TACE group when analyzed per branch (odds ratio [OR], 6.36; P < 0.001) and per patient (OR, 3.15; P = 0.005). For each HAD grade, the mean doxorubicin dose was greater in the DEB-TACE group than in the Conv-TACE group (P < 0.001, P = 0.053, and P = 0.01 for grades I, II, and III, respectively). In multivariate analysis, risk factors of HAD included mean doxorubicin dose and selective embolization in the Conv-TACE group (P = 0.03 and P < 0.001, respectively) and mean doxorubicin dose in the DEB-TACE group (P = 0.004). Conclusion The incidence and grade of HAD were higher after DEB-TACE compared to Conv-TACE with doxorubicin dose as a possible risk factor. HAD was independent of overall survival in both groups.
UR - http://www.scopus.com/inward/record.url?scp=85011597231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011597231&partnerID=8YFLogxK
U2 - 10.1177/0284185116648501
DO - 10.1177/0284185116648501
M3 - Article
VL - 58
SP - 131
EP - 139
JO - Acta Radiologica
JF - Acta Radiologica
SN - 0284-1851
IS - 2
ER -